Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Stanford University
With
National Heart, Lung, and Blood Institute (NHLBI)
American Heart Association
Age
18–89
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Male or female, aged 18-89
Patients must carry a diagnosis of heart failure with ejection fraction \< 40%
Be willing to participate in cardiac rehabilitation, and not already done so in the last year
Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration
Must be able to exercise on a treadmill
You may not be if
Inability to complete CPET or participate in CR (verbal/chart)
Syncope during CPET within the last 6 mos, sustained VT on CPET, hemodynamically significant arrhythmia during CPET (verbal/chart)
BMI \>= 38 (verbal/chart)
History of a bleeding disorder or clotting abnormality (verbal/chart)
Clinical diagnosis of severe Chronic Obstructive Pulmonary Disease (COPD) (verbal/chart)
History of malignancy not considered in remission (verbal/chart)
Cirrhosis (verbal/chart)
Thyroid disease (verbal/chart)
* Thyroid Stimulating Hormone (TSH) value outside of the normal range for the laboratory within the last 1 year
* Individuals with hypothyroidism may be referred to their primary care provider (PCP) for evaluation and retested; any medication change must be stable for ≥3 months prior to retesting
* Individuals with hyperthyroidism are excluded, including those with normal TSH on pharmacologic treatment
Cancer (verbal/chart)
* History of cancer treatment (other than non-melanoma skin cancer) and not "cancer-free" for at least 2 years
* Anti-hormonal therapy (e.g., for breast or prostate cancer) within the last 6 months
Chronic active or latent infection (verbal/chart)
* Active or latent infections requiring chronic antibiotic or anti-viral treatment
* Chronic active infection whether on chronic antimicrobials or not
* Human Immunodeficiency Virus
* Active hepatitis B or C undergoing antiviral therapy
* Individuals successfully treated for hepatitis C and virologically negative for at least 6 months are not excluded
Tobacco (verbal/chart)
* Current smokers: any tobacco or e-cigarette/e-nicotine products
* Former smokers: Stopped smoking \<6 months at time of screening
Not be pregnant or lactating in the last 12 months, or planning to become pregnant for the next 4 months. Not be post-partum during the last 12 months. (verbal/chart)
Metabolic bone disease (self-report): History of non-traumatic fracture from a standing height or less. Current pharmacologic treatment for low bone mass or osteoporosis, other than calcium, vitamin D, or estrogen. (verbal/chart)
Diabetes (self-report and screening), which includes: i) treatment with any insulin or ii) A1c \>=8.0 (screening). (verbal/chart)
Chronic renal insufficiency (screening): estimated glomerular filtration rate \<30 mL/min/1.73 m2 from serum creatinine (mg/dL) by the Chronic Kidney Disease Epidemiology Collaboration equation. (verbal/chart)
Individuals receiving any active treatment for autoimmune disorders (including monoclonal antibodies) within the last 6 months. (verbal/chart)
Alcohol consumption: i) more than 7 drinks per week for women and more than 14 drinks per week for men; ii) history of binge drinking. (verbal/chart)
Any individual engaging in night shift work in the last 6 months.
Hospitalization for any psychiatric condition within one year (verbal/chart)
Any musculoskeletal or ligamentous injury, amputation or congenital neurological defect that, in the opinion of the team clinician, would negatively impact or mitigate participation in and completion of the protocol. (verbal/chart)
Mental incapacity and/or cognitive impairment on the part of the participant that would inhibit adequate understanding of or cooperation with the study protocol
Other (clinician judgment)
* Genetic metabolic disorders that could affect metabolomic results (e.g., phenylketonuria)
* Any other cardiovascular, pulmonary, orthopedic, neurologic, psychiatric, metabolic, or other conditions that, in the opinion of the local clinician, would preclude participation and successful completion of the protocol
* Any other illnesses that, in the opinion of the local clinician, would negatively impact or mitigate participation in and completion of the protocol
* Any drugs used specifically to induce muscle growth/hypertrophy or augment exercise induced muscle hypertrophy
* Psychiatric
* Chronic use of medium- or long-acting sedatives and hypnotics, including all benzodiazepines; short-acting non-benzodiazepine sedative-hypnotics are allowed
